All Pathways
GastroenterologyEmergency

Acute Variceal Hemorrhage Management (Baveno VII 2022)

Acute Variceal Hemorrhage Management (Baveno VII 2022): Suspected Variceal Hemorrhage → Initial Resuscitation → Vasoactive Therapy → Timing of Endoscopy...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected Variceal Hemorrhage

    Patient with known/suspected cirrhosis presenting with hematemesis or melena

    1. Action

      Initial Resuscitation

      Hemodynamic stabilization and early pharmacotherapy

      • IV access x2, type and cross
      • Restrictive transfusion: target Hb 7-8 g/dL
      • Avoid over-resuscitation (increases portal pressure)
      • Start vasoactive drugs IMMEDIATELY (before EGD)
      1. Action

        Vasoactive Therapy

        Reduce portal pressure

        • Octreotide 50mcg bolus (optional), then 25-50mcg/hr IV continuous
        • OR Terlipressin 2mg IV q4h x 48h, then reduce to 1mg q4h
        • Continue for 2-5 days
        • Start BEFORE endoscopy
        1. Decision

          Timing of Endoscopy

          EGD within 12 hours of presentation

          • After initial stabilization
          • Erythromycin 250mg IV 30-120 min before
          • Improves visualization
          1. Action

            Esophageal Variceal Ligation (EVL)

            First-line endoscopic therapy for esophageal varices

            • Band ligation preferred over sclerotherapy
            • 4-8 bands per session typical
            • Repeat q2-4 weeks until eradication
            1. Decision

              Assess Rebleeding Risk

              High-risk features for early rebleeding

              • Child-Pugh C or MELD >19
              • Active bleeding at endoscopy
              • HVPG >20 mmHg (if measured)
              • Hepatic encephalopathy
              1. Action

                Early Pre-emptive TIPS

                Within 72 hours (ideally 24h) for high-risk patients

                • Child-Pugh C (10-13 points)
                • OR Child-Pugh B with active bleeding
                • Covered PTFE stents preferred
                • Reduces rebleeding and mortality
                1. Outcome

                  Bleeding Controlled

                  Continue secondary prophylaxis with NSBB + EVL until variceal eradication

                2. Outcome

                  Evaluate for Transplant

                  Refer to transplant center if decompensated cirrhosis

              2. Action

                Standard Medical Therapy

                Continue vasoactive drugs and NSBB after acute phase

                • Complete 5 days of vasoactive therapy
                • Start NSBB (propranolol/carvedilol) after day 5
                • Schedule EVL sessions q2-4 weeks
                • PPI for banding ulcers
                1. Warning

                  Rescue TIPS

                  For refractory/recurrent bleeding despite endoscopic therapy

                  • Failure of endoscopic hemostasis
                  • Rebleeding despite optimal therapy
                  • Bridge to transplant if appropriate
          2. Action

            Gastric Varices (GOV2/IGV)

            Cyanoacrylate injection or TIPS

            • Tissue adhesive (cyanoacrylate) injection
            • OR Early TIPS if available
            • EVL NOT effective for fundal varices
      2. Action

        Antibiotic Prophylaxis

        Reduce infection and rebleeding

        • Ceftriaxone 1g IV q24h (preferred in advanced cirrhosis)
        • OR Norfloxacin 400mg PO BID (if able to take PO)
        • Duration: 7 days
        • Reduces mortality
      3. Warning

        ⚠️ Airway Protection

        Consider intubation if massive hematemesis, altered mental status, or encephalopathy

Guideline Source

Baveno VII - Renewing consensus in portal hypertension

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Requires ICU-level monitoring for unstable patients
  • Endoscopy should be performed by experienced endoscopist
  • TIPS availability varies by institution
  • Antibiotic prophylaxis choice may vary regionally
  • Does not address secondary prophylaxis in detail

Contraindicated Populations

pediatric

Applicable Regions

USEUGlobal

EU: Baveno VII is European consensus standard

US: AASLD guidelines align with Baveno VII

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Acute Variceal Hemorrhage Management (Baveno VII 2022)?

The Acute Variceal Hemorrhage Management (Baveno VII 2022) is a emergency clinical algorithm for Gastroenterology. It provides a structured decision tree to guide clinical decision-making, based on Baveno VII - Renewing consensus in portal hypertension.

What guideline is the Acute Variceal Hemorrhage Management (Baveno VII 2022) based on?

This algorithm is based on Baveno VII - Renewing consensus in portal hypertension (DOI: 10.1016/j.jhep.2022.10.020).

What are the limitations of the Acute Variceal Hemorrhage Management (Baveno VII 2022)?

Known limitations include: Requires ICU-level monitoring for unstable patients; Endoscopy should be performed by experienced endoscopist; TIPS availability varies by institution; Antibiotic prophylaxis choice may vary regionally; Does not address secondary prophylaxis in detail. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Acute Variceal Hemorrhage Management (Baveno VII 2022) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free